Framing the cGVHD Landscape

Dr. DeFilipp focuses on treatment selection and sequencing for chronic graft-versus-host disease (cGVHD) following allogeneic transplantation, with an emphasis on later-line management and emerging therapies. He underscores that cGVHD remains the most significant long-term immunologic complication after transplant and continues to pose diagnostic and therapeutic challenges despite recent advances.

The segment contextualizes the evolving treatment landscape, noting that historical reliance on broad immunosuppression is being replaced by targeted agents supported by randomized trials. Dr. DeFilipp highlights the importance of integrating both clinical trial data and real-world experience when making treatment decisions, as patients encountered in practice often differ from those enrolled in registrational studies. He emphasizes that treatment goals extend beyond response rates to include durability, steroid-sparing effects, organ preservation, and quality of life.

cGVHD is a heterogeneous, chronic condition requiring individualized, longitudinal management rather than a one-size-fits-all approach.